The current status of biological treatment for uveitis

References

• Fabiani C, Vitale A, Orlando I, et al. Impact of uveitis on quality of life: a prospective study from a tertiary referral rheumatology-ophthalmology collaborative uveitis center in Italy. Isr Med Assoc J. 2017;19(8):478–483.
   PubMed Web of Science ®Google Scholar
• De Parisot A, Kodjikian L, Errera MH, et al. Randomized controlled trial evaluating a standardized strategy for uveitis etiologic diagnosis (ULISSE). Am J Ophthalmol. 2017;178:176–185.
   PubMed Web of Science ®Google Scholar
• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26:2–16.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001;80(4):263–270.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Deschenes J, Murray PI, Rao NA, et al. International uveitis study group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1–2.
   PubMed Web of Science ®Google Scholar
• Forrester JV, Klaska IP, Yu T, et al. Uveitis in mouse and man. Int Rev Immunol. 2013;32(1):76–96.
   PubMed Web of Science ®Google Scholar
• Forrester JV, Kuffova L, Dick AD. Autoimmunity, autoinflammation, and infection in uveitis. Am J Ophthalmol. 2018;189:77–85.
   PubMed Web of Science ®Google Scholar
• Forrester JV, Stott DI, Hercus KM. Naturally occurring antibodies to bovine and human retinal S antigen: a comparison between uveitis patients and healthy volunteers. Br J Ophthalmol. 1989;73(2):155–159.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol. 2013;156(2):228–236.
   PubMed Web of Science ®Google Scholar
• Krishna U, Ajanaku D, Denniston AK, et al. Uveitis: a sight-threatening disease which can impact all systems. Postgrad Med J. 2017;93(1106):766–773.
   PubMed Web of Science ®Google Scholar
• Foster CS, Kothari S, Anesi SD, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61(1):1–17.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr, Abu El Asrar AM, Takeuchi M, et al. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. Int Ophthalmol. 2019;39(6):1419–1425.
   PubMed Web of Science ®Google Scholar
• Airody A, Heath G, Lightman S, et al. Non-infectious uveitis: optimising the therapeutic response. Drugs. 2016;76(1):27–39.
   PubMed Web of Science ®Google Scholar
• Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol. 2009;19(6):998–1003.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet. 2001;358(9278):295–296.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. Clin Exp Rheumatol. 2019;37(2):301–305.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3.
   PubMed Web of Science ®Google Scholar
• Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology. 2018;125(5):757‐73.
   Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608.
   PubMed Web of Science ®Google Scholar
• Freeman K, Taylor-Phillips S, Connock M, et al. Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn’s disease: a systematic review and meta-analysis. BMJ Open. 2017;7(6):e014581.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). 2009;23(9):1868–1870.
   PubMed Web of Science ®Google Scholar
• Joshi L, Talat L, Yaganti S, et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis. Ophthalmology. 2014;121(5):1119–1124.
   PubMed Web of Science ®Google Scholar
• Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a meta-analysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42:2229–2237.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481‐6.
   PubMed Web of Science ®Google Scholar
• Durrani K, Kempen JH, Ying GS, et al. Systemic immunosuppressive therapy for eye diseases site research group. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. 2017;25(3):405–412.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24(3):351‐61.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696‐701.
   Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575‐81.
   PubMed Web of Science ®Google Scholar
• Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97(2):134‐8.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183‐9.
   Web of Science ®Google Scholar
• Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511‐8.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102(5):637‐41.
   PubMed Web of Science ®Google Scholar
• Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s Disease. Ophthalmology. 2018;125(9):1444‐51.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Heinz C, Jakob E, et al. Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis. Ocul Immunol Inflamm. 2018;26(7):1015‐22.
   Web of Science ®Google Scholar
• Silvestri E, Bitossi A, Bettiol A, et al. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome. Inflammopharmacology. 2020;28(3):711–718.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol. 2019;38(1):63–70.
   PubMed Web of Science ®Google Scholar
• Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110(7):1449–1453.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111(2):352–356.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kalkamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140(5):404–406.
   PubMed Web of Science ®Google Scholar
• El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27–associated acute anterior uveitis. Ophthalmology. 2002;109(12):2342–2346.
   PubMed Web of Science ®Google Scholar
• Fries W, Giofre MR. Catonoso, et al. Treatment of acute uveitis with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97(2):499–500.
   PubMed Web of Science ®Google Scholar
• Goossens PH, Verburg RJ, Breedvold FC. Remission of Behçet’s syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001;60(6):637.
   PubMed Web of Science ®Google Scholar
• Sayarliogu M, Cinal A, Topcu A, et al. Effect of infliximab on refractory uveitis in Behçet’s disease. Ann Pharmacother. 2004;38(5):901–902.
   Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533–536.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912.
   PubMedGoogle Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127(6):819–822.
   PubMed Web of Science ®Google Scholar
• Maleki A, Sahawneh HF, Ma L, et al. Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina. 2017;37(5):836–843.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478–2484.
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial. Rheumatol Int. 2008;29(1):53–57.
   PubMed Web of Science ®Google Scholar
• Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474–484.
   PubMed Web of Science ®Google Scholar
• Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31(1):33–37.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593–597.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Vitale A, et al. Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm. 2019;27(1):34‐9.
   Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121(10):1877–1884.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol. 2004;122(6):845‐51.
   PubMedGoogle Scholar
• Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130(5):592‐8.
   PubMedGoogle Scholar
• Ohno S, Umebayashi I, Matsukawa M, et al. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21(1):2.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol. 2016;68(6):1522–1530.
   PubMed Web of Science ®Google Scholar
• Lejoyeux R, Diwo E, Vallet H, et al. Infliximab and Adalimumab in Uveitic Macular Edema. Ocul Immunol Inflamm. 2018;26(7):991–996.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol. 2018;37(10):2805–2809.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s Disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081–2089.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223‐31.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Salom D, Díaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology. 2011;118(9):1892.e3-4.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31(2):320–321.
   PubMed Web of Science ®Google Scholar
• van Bentum RE, Heslinga SC, Nurmohamed MT, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - the GO-EASY study. J Rheumatol. 2019;46(2):153–159.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95–101.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s Disease. Ocul Immunol Inflamm. 2019;27(1):58–63.
   PubMed Web of Science ®Google Scholar
• Tosi GM, Sota J, Vitale A, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37(4):680–683.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90‐5.
   Web of Science ®Google Scholar
• Cordero-Coma M, Calvo-Río V, Adán A, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. 2014;717598:2014.
   Google Scholar
• Yazgan S, Celik U, Işık M, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139‐45.
   PubMed Web of Science ®Google Scholar
• Llorenç V, Mesquida M, Sainz de la Maza M, et al. Certolizumab Pegol, a new anti-TNF-α in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm. 2016;24(2):167–172.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rosenbaum JT, Landewé R, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838–844.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study. Mod Rheumatol. 2017;27(6):1031–1035.
   PubMed Web of Science ®Google Scholar
• Smith BJ, McMillan VM, Newton JS. Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. J Clin Rheumatol. 2001;7(3):175–178.
   PubMed Web of Science ®Google Scholar
• Manzano RP, Carvounis PE, Albini TA, et al. Etanercept monotherapy induces complete resolution of cystoid macular edema in a patient with intermediate uveitis. Retin Cases Brief Rep. 2007;1(4):261–263.
   PubMedGoogle Scholar
• Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol. 2009;53(4):439–440.
   PubMed Web of Science ®Google Scholar
• Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87(7):925.
   PubMed Web of Science ®Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248–3252.
   PubMed Web of Science ®Google Scholar
• Raffeiner B, Ometto F, Bernardi L, et al. Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept. Case Rep Med. 2014;2014:471319.
   PubMedGoogle Scholar
• Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010;69(1):226–229.
   PubMed Web of Science ®Google Scholar
• Khoury G, Morel J, Combe B, et al. Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort. Arthritis Res Ther. 2020;22(1):94.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437–440.
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631–1634.
   PubMed Web of Science ®Google Scholar
• Lie E, Lindström U, Zverkova-Sandström T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017;76(9):1515–1521.
   PubMed Web of Science ®Google Scholar
• Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515–2521.
   PubMed Web of Science ®Google Scholar
• Leal I, Rodrigues FB, Sousa DC, et al. Anti-TNF drugs for chronic uveitis in adults-a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2019;6:104.
   PubMed Web of Science ®Google Scholar
• Kötter I, Eckstein AK, Stübiger N, et al. Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol. 1998;82(5):488–494.
   PubMed Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423–431.
   PubMed Web of Science ®Google Scholar
• Kötter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33(5):311–319.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet Disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–471.
   PubMed Web of Science ®Google Scholar
• Hasanreisoglu M, Cubuk MO, Ozdek S, et al. Interferon alpha-2a therapy in patients with refractory Behçet Uveitis. Ocul Immunol Inflamm. 2017;25(1):71–75.
   PubMed Web of Science ®Google Scholar
• Yalçindag N, Köse HC. Comparison of the treatment results for Behçet uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm. 2020;28(2):305–314.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Koetter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26(7):786–791.
   PubMed Web of Science ®Google Scholar
• Fardeau C, Simon A, Rodde B, et al. Interferon-alpha2a and systemic corticosteroid in monotherapy in chronic uveitis: results of the randomized controlled BIRDFERON study. Am J Ophthalmol. 2017;177:182–194.
   PubMed Web of Science ®Google Scholar
• Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89(10):1254–1257.
   PubMed Web of Science ®Google Scholar
• Velazquez-Villoria D, Macia-Badia C, Segura-García A, et al. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis. Arch Soc Esp Oftalmol. 2017;92(6):273–279.
   PubMedGoogle Scholar
• Jouve L, Benrabah R, Héron E, et al. Multiple sclerosis-related uveitis: does MS treatment affect uveitis course? Ocul Immunol Inflamm. 2017;25(3):302–307.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478–86.e1.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692‐5.
   Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335‐9.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55‐61.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129(3):288‐94.
   Google Scholar
• Yang P, Huang G, Du L, et al. Long-term efficacy and safety of interferon alpha-2a in the treatment of chinese patients with Behçet’s Uveitis not responding to conventional therapy. Ocul Immunol Inflamm. 2019;27(1):7‐14.
   Web of Science ®Google Scholar
• Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885–1891.
   PubMed Web of Science ®Google Scholar
• Cao JH, Oray M, Cocho L, et al. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol. 2016;164:22–28.
   PubMed Web of Science ®Google Scholar
• You C, Ma L, Lasave AF, et al. Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener’s). Ocul Immunol Inflamm. 2018;26(8):1166–1173.
   PubMed Web of Science ®Google Scholar
• Lin M, Anesi SD, Ma L, et al. Characteristics and visual outcome of refractory retinal vasculitis associated with antineutrophil cytoplasm antibody-associated vasculitides. Am J Ophthalmol. 2018;187:21–33.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial. JAMA Ophthalmol. 2014;132(5):572–578.
   PubMed Web of Science ®Google Scholar
• Derzko-dzulynsky L. IgG4-related disease in the eye and ocular adnexa. Curr Opin Ophthalmol. 2017;28(6):617–622.
   PubMed Web of Science ®Google Scholar
• You C, Lamba N, Lasave AF, et al. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1221–1228.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. 2015;34(10):1817–1820.
   PubMed Web of Science ®Google Scholar
• Cornish KS, Kuffova L, Forrester JV. Treatment of diffuse subretinal fibrosis uveitis with rituximab. Br J Ophthalmol. 2015;99(2):153–154.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol. 2012;6:1613–1618.
   PubMedGoogle Scholar
• Eid L, Coste-Verdier V, Longueville E, et al. The effects of Rituximab on Graves’orbitopathy: A retrospective study of 14 patients. Eur J Ophthalmol. 2019;26:1120672119845224.
   Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246–252.
   PubMed Web of Science ®Google Scholar
• Lasave AF, You C, Ma L, et al. Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy. Retina. 2018;38(2):395–402.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019;61(1):44–50.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–473.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Fabiani C, Sota J, et al. IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol. 2017;36(7):1459–1469.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Bella CD, et al. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behçet patients and exhibit high levels of TNF-alpha in early phases of the disease. Medicine (Baltimore). 2016;95(49):e5516.
   PubMed Web of Science ®Google Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–1835.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–6.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856–864.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380–2386.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4):S75–9.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38(7):1361–1370.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.
   PubMed Web of Science ®Google Scholar
• Hassan M, Nguyen NV, Halim MS, et al. Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis. J Ophthalmic Inflamm Infect. 2019;9(1):12.
   PubMed Web of Science ®Google Scholar
• Wendling D, Dernis E, Prati C, et al. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011;38(10):2284.
   PubMed Web of Science ®Google Scholar
• Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428–437.
   PubMed Web of Science ®Google Scholar
• Trittibach P, Barker SE, Broderick CA, et al. Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther. 2008;15(22):1478–1488.
   PubMed Web of Science ®Google Scholar
• Tsai ML, Horng CT, Chen SL, et al. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis. 2009;15:1542–1552.
   PubMed Web of Science ®Google Scholar
• Biswas PS, Banerjee K, Kim B, et al. Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. J Immunol. 2004;172(6):3736–3744.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Tosi GM, et al. The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol. 2017;36(10):2307–2318.
   PubMed Web of Science ®Google Scholar
• Zhao B, Chen W, Jiang R, et al. Expression profile of IL-1 family cytokines in aqueous humor and sera of patients with HLA-B27 associated anterior uveitis and idiopathic anterior uveitis. Exp Eye Res. 2015;138:80–86.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behçet’s Disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–1033.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301.
   PubMed Web of Science ®Google Scholar
• Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–1286.
   PubMed Web of Science ®Google Scholar
• Orlando I, Vitale A, Rigante D, et al. Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. Intern Med J. 2017;47(9):1086–1088.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Cameli AM, et al. Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol. 2013;31(3):152–153.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Ciucciarelli L, et al. Reply: anti-IL1 blocking agents in drug-resistant Behçet’s syndrome: our little case series. Clin Exp Rheumatol. 2014;32(4):S172.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Efficacy of anakinra in refractory Behçet’s disease sacroiliitis. Clin Exp Rheumatol. 2014;32(4):S171.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Long-term efficacy and safety of anakinra in a patient with Behçet’s disease and concomitant tuberculosis infection. Int J Dermatol. 2017;56(2):218–220.
   PubMed Web of Science ®Google Scholar
• Pagnini I, Bondi T, Simonini G, et al. Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease. Rheumatology (Oxford). 2015;54(7):1327–1328.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology. 2014;228(3):211–214.
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589–1591.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191–197.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Behçet’s Disease. Ocul Immunol Inflamm. 2020;28(2):298–304.
   PubMed Web of Science ®Google Scholar
• Sota J, Vitale A, Insalaco A, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37(8):2233–2240.
   PubMed Web of Science ®Google Scholar
• Shao H, Woon MD, Nakamura S, et al. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci. 2001;42(9):2016–2021.
   PubMed Web of Science ®Google Scholar
• Silver PB, Hathcock KS, Chan CC, et al. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol. 2000;165(9):5041–5047.
   PubMed Web of Science ®Google Scholar
• Iwahashi C, Fujimoto M, Nomura S, et al. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: comparison with blockade of interleukin-6. Exp Eye Res. 2015;140:53–64.
   PubMed Web of Science ®Google Scholar
• Suhler E, Giles T, Hanel S, et al. A phase I/II dose-ranging, randomized clinical trial of abatacept (Orencia) in the treatment of refractory non-infectious uveitis: preliminary results. Invest Ophthalmol Vis Sci. 2013;54:5190.
   Web of Science ®Google Scholar
• Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821–825.
   PubMed Web of Science ®Google Scholar
• Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. J Rheumatol. 2016;43(11):2068–2073.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015;42(4):706–711.
   PubMed Web of Science ®Google Scholar
• Guedes MC, Borrego LM, Proença RD. Roles of interleukin-17 in uveitis. Indian J Ophthalmol. 2016;64(9):628–634.
   PubMed Web of Science ®Google Scholar
• Pepple KL, Lin P. Targeting Interleukin-23 in the treatment of noninfectious uveitis. Ophthalmology. 2018;125(12):1977–1983.
   PubMed Web of Science ®Google Scholar
• Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13(6):711–718.
   PubMed Web of Science ®Google Scholar
• Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behçet’s disease patients: relationship with disease activity. Scand J Rheumatol. 2002;31(4):205–210.
   PubMed Web of Science ®Google Scholar
• Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49(7):3058–3064.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(62):52ra72.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939–948.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017;30(5). DOI:10.1111/dth.12527
   PubMed Web of Science ®Google Scholar
• Chateau T, Angioi K, Peyrin-Biroulet L. Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn’s disease. J Crohns Colitis. 2020;14(4):571.
   PubMed Web of Science ®Google Scholar
• Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491–493.
   PubMed Web of Science ®Google Scholar
• Ooi KG, Galatowicz G, Calder VL, et al. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res. 2006;4(4):294–309.
   PubMedGoogle Scholar
• Chen W, Zhao B, Jiang R. Cytokine expression profile in aqueous humor and sera of patients with acute anterior uveitis. Curr Mol Med. 2015;15(6):543–549.
   PubMed Web of Science ®Google Scholar
• Velez G, Roybal CN, Colgan D, et al. Precision medicine: personalized proteomics for the diagnosis and treatment of idiopathic inflammatory disease. JAMA Ophthalmol. 2016;134(4):444–448.
   PubMed Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53–55.
   PubMedGoogle Scholar
• Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator. Eur J Rheumatol. 2017;4(4):288–290.
   PubMed Web of Science ®Google Scholar
• Dincses E, Esatoglu SN, Ozguler Y, et al. Biosimilar infliximab for Behçet’s syndrome: a case series. Clin Exp Rheumatol. 2019;37(6 Suppl 121):111–115.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Venerito V, Cantarini L, et al. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease. Intern Emerg Med. 2019;14(5):719–722.
   PubMed Web of Science ®Google Scholar
• Avouac J, Moltó A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin university hospital, Paris, France. Semin Arthritis Rheum. 2018;47(5):741–748.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors. Front Pharmacol. 2019;10:1468.
   PubMed Web of Science ®Google Scholar
• C, Sota J, Sainz-de-la-Maza M, et al. New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators Inflamm. 2020;2020:8294560.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Sainz-de-la-Maza M, et al. New potential weapons for refractory scleritis in the era of targeted therapy. Mediators Inflamm. 2020;2020:8294560.
   PubMed Web of Science ®Google Scholar